The DOI matches its Crossref record; 210 of the 210 references it cites were found in a registry or an index.
DNA mismatch repair in cancer
Abstract
Microsatellite instability (MSI) refers to the hypermutator phenotype secondary to frequent polymorphism in short repetitive DNA sequences and single nucleotide substitution, as consequence of DNA mismatch repair (MMR) deficiency. MSI secondary to germline mutation in DNA MMR proteins is the molecular fingerprint of Lynch syndrome (LS), while epigenetic inactivation of these genes is more commonly found in sporadic MSI tumors. MSI occurs at different frequencies across malignancies, although original methods to assess MSI or MMR deficiency have been developed mostly in LS related cancers. Here we will discuss the current methods to detect MSI/MMR deficiency with a focus of new tools which are emerging as highly sensitive detector for MSI across multiple tumor types. Due to high frequencies of non‐synonymous mutations, the presence of frameshift‐mutated neoantigens, which can trigger a more robust and long‐lasting immune response and strong TIL infiltration with tumor eradication, MSI has emerged as an important predictor of sensitivity for immunotherapy‐based strategies, as showed by the recent FDA's first histology agnostic‐accelerated approval to immune checkpoint inhibitors for refractory, adult and pediatric, MMR deficient (dMMR) or MSI high (MSI‐H) tumors. Moreover, it is known that MSI status may predict cancer response/resistance to certain chemotherapies. Here we will describe the complex interplay between the genetic and clinical‐pathological features of MSI/dMMR tumors and the cancer immunotherapy, with a focus on the predictive and prognostic role of MMR status for immune checkpoint inhibitors (ICIs) and providing some suggestions on how to conceive better predictive markers for immunotherapy in the next future.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Items 201–210 of 210
Kim, K.-J., Yang, H. K., Kim, W. H., & Kang, G. H. (2017) · Oncotarget · doi:10.18632/oncotarget.19439 · Cited by 33
Wang, T., Stadler, Z. K., Zhang, L., Weiser, M. R., Baştürk, O., Hechtman, J. F., Vakiani, E., Saltz, L. B., Klimstra, D. S., & Shia, J. (2017) · Familial Cancer · doi:10.1007/s10689-017-0031-9 · Cited by 30
Impact of mismatch-repair deficiency on the colorectal cancer immune microenvironment
Zhang, Y., Sun, Z., Mao, X., Wu, H., Luo, F., Wu, X., Zhou, L., Qin, J., Zhao, L., & Bai, C. (2017) · Oncotarget · doi:10.18632/oncotarget.20241 · Cited by 28
Glavač, D. (2003) · Cancer Genetics and Cytogenetics · doi:10.1016/s0165-4608(03)00109-2 · Cited by 27
Onda, M., Nakamura, I., Suzuki, S., Takenoshita, S., Brogren, C., Stampanoni, S., Li, D., & Rampino, N. J. (2001) · PubMed · Cited by 27
Miyaki, M., Iijima, T., Yamaguchi, T., Kadofuku, T., Funata, N., & Mori, T. (2004) · Cancer Letters · doi:10.1016/j.canlet.2004.01.027 · Cited by 25
Le, D. T., Yoshino, T., Jäger, D., André, T., Bendell, J. C., Wang, R., Kang, S. P., Koshiji, M., & Diaz, L. A. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2016.34.4_suppl.tps787 · Cited by 23
Self-citationFlahec, G. L., Badic, B., Guibourg, B., Doucet, L., Bail, J. P., Marcorelles, P., Schick, U., & Uguen, A. (2017) · Human Pathology · doi:10.1016/j.humpath.2017.09.019 · Cited by 23
Faulkner, R. D., Seedhouse, C., Das-Gupta, E. P., & Russell, N. H. (2003) · British Journal of Haematology · doi:10.1046/j.1365-2141.2003.04750.x · Cited by 17
Lee, P. J., McNulty, S. N., Duncavage, E. J., Heusel, J. W., & Hagemann, I. S. (2017) · International Journal of Gynecological Pathology · doi:10.1097/pgp.0000000000000459 · Cited by 5
Cited by
Luchini, C., Bibeau, F., Ligtenberg, M. J. L., Singh, N., Nottegar, A., Bosse, T., Miller, R., Riaz, N., Douillard, J.-Y., Andre, F., et al. (2019) · Annals of Oncology · doi:10.1093/annonc/mdz116 · Cited by 1,041
Quantitative Proteomics of the Cancer Cell Line Encyclopedia
Nusinow, D. P., Szpyt, J., Ghandi, M., Rose, C. M., McDonald, E. R., Kalocsay, M., Jané-Valbuena, J., Gelfand, E., Schweppe, D. K., Jedrychowski, M., et al. (2020) · Cell · doi:10.1016/j.cell.2019.12.023 · Cited by 957
“Additionally, these tumors have increased levels of neoantigens making them attractive for immunooncology therapies (Baretti and Le, 2018).”
The multi-factorial nature of clinical multidrug resistance in cancer
Assaraf, Y. G., Brozovic, A., Gonçalves, A. C., Jurkovicova, D., Linē, A., Machuqueiro, M., Saponara, S., Sarmento-Ribeiro, A. B., Xavier, C. P. R., & Vasconcelos, M. H. (2019) · Drug Resistance Updates · doi:10.1016/j.drup.2019.100645 · Cited by 528
Sun, J.-Y., Zhang, D., Wu, S., Xu, M., Zhou, X., Lu, X.-J., & Ji, J. (2020) · Biomarker Research · doi:10.1186/s40364-020-00212-5 · Cited by 279
Mismatch Repair Pathway, Genome Stability and Cancer
Pećina-Šlaus, N., Kafka, A., Salamon, I., & Bukovac, A. (2020) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2020.00122 · Cited by 278
Metadata
- Authors
- Baretti, M., & Le, D. T.
- Venue
- Pharmacology & Therapeutics
- Publisher
- Elsevier BV
- Published
- 2018-09
- Volume
- 189
- Pages
- 45-62
- ISSN
- 0163-7258 (ISSN-L)
- OpenAlex
- W2796494201
- Cited by
- 556
- References
- 210
- FWCI
- 24.10
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.